Alendronate improves fasting plasma glucose and insulin sensitivity, and decreases insulin resistance in prediabetic osteopenic postmenopausal women: A randomized triple‐blind clinical trial
Open Access
- 29 September 2018
- journal article
- clinical trial
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 10 (3) , 731-737
Abstract
Aims/Introduction: Postmenopausal women receive bisphosphonates for osteoporosis treatment. The effect of these medications on developing diabetes mellitus in prediabetic patients is yet to be investigated. We aimed to determine the effect of alendronate on plasma glucose, insulin indices of postmenopausal women with prediabetes and osteopenia.Materials and Methods: The present triple‐blind randomized controlled clinical trial included 60 postmenopausal women, aged 45–60 years. All patients were vitamin D sufficient. They were randomly enrolled in intervention (70 mg/week alendronate for 12 weeks) and control (placebo tablet per week for 12 weeks) groups. The morning 8‐h fasting blood samples were collected at the baseline and follow‐up visits to measure the fasting plasma glucose (mg/dL), insulin and hemoglobin A1c (HbA1c). Plasma glucose and insulin concentration were measured 30, 60 and 120 min after the glucose tolerance test. The Matsuda Index, homeostasis model assessment of insulin resistance, homeostasis model assessment of β‐cell function and the area under the curves of glucose and insulin were calculated.Results: The mean (standard deviation) fasting plasma glucose (102.43 [1.46] mg/dL vs 94.23 [1.17] mg/dL, P = 0.001), 120‐min insulin concentration (101.86 [15.70] mU/L vs 72.60 [11.36] mU/L, P = 0.026), HbA1c (5.60 [0.06]% vs 5.40 [0.05]%, P = 0.001), homeostasis model assessment of insulin resistance (3.57 [0.45] vs 2.62 [0.24], P = 0.021) and Matsuda Index (7.7 [0.41] vs 9.2 [0.4], P = 0.001) significantly improved in the alendronate‐treated group. There were more statistically significant reductions in fasting plasma glucose (−8.2 [8.63] mg/dL vs −2.5 [14.26] mg/dL, P = 0.002) and HbA1c (−0.2 [0.23]% vs −0.09 [0.26]%, P = 0.015) observed in the alendronate‐treated group than the placebo group during the study course, respectively.Conclusions: Administration of 70 mg/week alendronate improves fasting plasma glucose, HbA1c and insulin indices in postmenopausal women.Keywords
Funding Information
- Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences (1395.3.292)
This publication has 29 references indexed in Scilit:
- Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trialsJournal of Bone and Mineral Research, 2013
- Bone and glucose metabolism: A two-way streetArchives of Biochemistry and Biophysics, 2010
- A1C Level and Future Risk of Diabetes: A Systematic ReviewDiabetes Care, 2010
- Insulin Signaling in Osteoblasts Integrates Bone Remodeling and Energy MetabolismCell, 2010
- The global burden of diabetes and its complications: an emerging pandemicEuropean Journal of Preventive Cardiology, 2010
- FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in miceJournal of Clinical Investigation, 2010
- Bisphosphonates: Mechanism of Action and Role in Clinical PracticeMayo Clinic Proceedings, 2008
- The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up studyThe Lancet, 2008
- Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type miceProceedings of the National Academy of Sciences, 2008
- Endocrine Regulation of Energy Metabolism by the SkeletonCell, 2007